Sarma1 2
STALICLA appoints Dr. Purnanand Sarma, PhD, as Chair of the Board of Directors
July 09, 2024 07:00 ET | STALICLA
Press Release Dr. Sarma brings exceptional expertise in all facets of the pharmaceutical and biotechnology business, from scaling platforms to developing therapeutics Geneva, Switzerland – July 9,...
DP World's Aviv Clinics Dubai’s Revolutionary Youth Protocol
Transforming Children's Lives: DP World's Aviv Clinics Dubai’s Revolutionary Youth Protocol
July 07, 2024 21:00 ET | Aviv Clinics
DUBAI, United Arab Emirates, July 07, 2024 (GLOBE NEWSWIRE) -- At DP World's Aviv Clinics Dubai, the world’s most advanced brain and body performance clinic, we understand the heartache parents feel...
Stalilcla logo.png
STALICLA publishes pioneering phase 1b data on precision treatment for autism spectrum disorder in Biomedicines
June 27, 2024 07:10 ET | STALICLA
Press Release STALICLA’s precision psychiatry study highlights strong EEG-based target engagement of STP1 treatment in defined subgroup of patients with autism and numerical improvement in core...
Catalight Practice G
Catalight Practice Guidelines Reflect a Contemporary Research View of the Dosage Effect and Outcome Measures in Autism Care
April 23, 2024 17:28 ET | Catalight
WALNUT CREEK, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Catalight, one of the largest behavioral health networks in the United States working to support individuals with autism and intellectual and...
2022_CAI_Logo_Blue.png
Huntington Bancshares Incorporated Hires Three Neurodiverse Teams Fulltime in Technology with CAI Neurodiverse Solutions
April 17, 2024 09:00 ET | CAI
CAI today announced that Huntington Bank hired three teams of neurodivergent individuals fulltime through CAI Neurodiverse Solutions.
PaxMedica logo.jpg
PaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA Submission
April 11, 2024 16:30 ET | PaxMedica, Inc.
TARRYTOWN, New York, April 11, 2024 (GLOBE NEWSWIRE) -- via IBN – PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today...
PaxMedica logo.jpg
PaxMedica Updated Company Presentation Highlighting Innovations in Autism Spectrum Disorder Treatments
March 13, 2024 08:20 ET | PaxMedica, Inc.
TARRYTOWN, New York, March 13, 2024 (GLOBE NEWSWIRE) -- via IBN – PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today...
Horizontal-Logo-Tagline Lockup-onWhitebkd-01 (6)[31].png
BlueSprig Pediatrics Sponsors Armani Williams Ahead of the Daytona ARCA 200
February 12, 2024 09:00 ET | BlueSprig Pediatrics, Inc.
DAYTONA BEACH, Fla., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Blue Sprig Pediatrics, Inc. (BlueSprig), a leader in Applied Behavior Analysis (ABA) therapy for children diagnosed with Autism Spectrum...
Stalilcla logo.png
Stalicla Secures $17.4 Million in Series B Financing to Propel Precision Neuro Advancements
January 16, 2024 06:00 ET | STALICLA
Geneva, Switzerland, January 16th, 2024 – Stalicla SA, a clinical-stage biopharmaceutical company advancing precision medicine pipelines for neuropsychiatric and neurological disorders, announces the...
Xolv
Xolv Creates a New Venture to Embark on New Era of Innovation in Behavioral Health
January 03, 2024 16:53 ET | Xolv
WALNUT CREEK, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Xolv, formerly Catalight’s IT and technology innovation group, proudly announces its transition to a new corporation today as part of a...